npj Parkinson's Disease (Nov 2021)

Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis

  • J. M. Hatcher-Martin,
  • J. L. McKay,
  • A. F. Pybus,
  • B. Sommerfeld,
  • J. C. Howell,
  • F. C. Goldstein,
  • L. Wood,
  • W. T. Hu,
  • S. A. Factor

DOI
https://doi.org/10.1038/s41531-021-00247-x
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 7

Abstract

Read online

Abstract We explore the association between three Alzheimer’s disease-related and ten inflammation-related CSF markers and freezing of gait (FOG) in patients with Parkinson’s disease (PD). The study population includes PD patients with FOG (PD-FOG, N = 12), without FOG (PD-NoFOG, N = 19), and healthy controls (HC, N = 12). Age and PD duration are not significantly different between groups. After adjusting for covariates and multiple comparisons, the anti-inflammatory marker, fractalkine, is significantly decreased in the PD groups compared to HC (P = 0.002), and further decreased in PD-FOG compared to PD-NoFOG (P = 0.007). The Alzheimer’s disease-related protein, Aβ42, is increased in PD-FOG compared to PD-NoFOG and HC (P = 0.001). Group differences obtained in individual biomarker analyses are confirmed with multivariate discriminant partial least squares regression (P < 0.001). High levels of Aβ42 in PD-FOG patients supports an increase over time from early to advanced state. Low levels of fractalkine might suggest anti-inflammatory effect. These findings warrant replication.